News | Ultrasound Women's Health | November 19, 2018

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

Completes first joint installation of AI-based system for concurrent reading with Invenia ABUS from GE Healthcare

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

November 19, 2018 – QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (AI) computer-aided detection (CAD) system for concurrent reading of automated breast ultrasound (ABUS) exams, at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25-30, in Chicago. Being demonstrated for the first time since being approved, QVCAD reduces interpretation time of screening ABUS exams while maintaining diagnostic accuracy.  

In addition, QView successfully completed an installation of QVCAD at Northern Arizona Healthcare, the first joint installation with the Invenia ABUS system from GE Healthcare. Invenia ABUS is approved by the FDA for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breasts. “We are excited to add the capability to offer ABUS as part of our comprehensive breast cancer screening program, which will help improve cancer detection for women with dense breasts. However, it was important that we implement with concurrent decision support from QVCAD to improve reading times while maintaining workflow and diagnostic confidence,” said Liz Palomino, MHA, RT, Northern Arizona Healthcare director of medical imaging, Flagstaff Medical Center, Sedona Medical Center, Verde Valley Medical Center and Verde Valley Medical Imaging Center.

Results from several clinical studies have shown that the addition of ABUS to screening mammography results in a significant increase in cancer detection in women with dense breasts. However, the interpretation of ABUS exams, with up to 2,000 images per case, is complex and time consuming, particularly for new users. According to results of a reader study published recently in the American Journal of Radiology, QVCAD reduced reader interpretation time by 33 percent while maintaining diagnostic accuracy.

Based on deep learning algorithms, the AI system is designed to detect suspicious areas of breast tissue with characteristics similar to breast lesions, and highlight suspicious area to distinguish potentially malignant lesions from normal breast tissue.  QVCAD is FDA-approved for use with ABUS systems and has received the CE mark for use with ABUS/ABVS systems.

To improve reader productivity, QVCAD provides synthetic 2-D images of all six volumetric datasets in a standard ABUS exam to provide an immediately visual overview of the case. The C-thru images, which are minimum intensity projections (MinIP), summarize each 3-D ABUS volume in a 2-D image. They bring attention to specific areas of interest by enhancement of radial spiculations and retraction patterns in coronal reconstructions, which are highly suggestive of breast cancer in ABUS. Users may select any CAD mark or area of interest on the C-thru image and the corresponding original ABUS images will be displayed, enabling users to efficiently review the entire ABUS case.

For more information: www.qviewmedical.com

Related Content

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

Feature | Breast Biopsy Systems | October 17, 2019 | By Harriet Borofsky, M.D.
The current body of research supporting...
An illustration of radiology department analytics data showing GE Healthcare’s business analytics software.

An illustration of radiology department analytics data showing GE Healthcare’s business analytics software.

Feature | Radiology Business | October 17, 2019 | By April Wilson
According to IBM, the world creates 2.5 quintillion bytes of data daily.
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Chesapeake Regional Healthcare Adds Agfa DR 800 X-ray Room
News | Digital Radiography (DR) | October 16, 2019
Agfa HealthCare announced the installation of its DR 800 multipurpose X-ray room at Chesapeake Regional Medical Center...
Feature | Artificial Intelligence | October 16, 2019 | By Siddharth (Sid) Shah
The period between November through February is pretty interesting for the field of medical imaging — two major confe
Feature | Breast Imaging | October 16, 2019 | By Jeff Zagoudis
On Jan. 1, 2017, the U.S.
Sponsored Content | Webinar | Analytics Software | October 11, 2019
Today’s healthcare providers understand that becoming “data-driven’ is imperative to continued success. In this webinar...